| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | KNS; KINH; KNS1; UKHC; HEL-S-61 |
| Entrez GeneID | 3799 |
| WB Predicted band size | Calculated MW: 110 kDa; Observed MW: 110 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human KIF5B |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3-4条关于KIF5B抗体的参考文献及其摘要概括：
---
1. **文献名称**：*Identification of a novel KIF5B-RET fusion in lung adenocarcinoma by antibody-based proteomic screening*
**作者**：Takeuchi K, et al.
**摘要**：该研究通过免疫沉淀(IP)和Western blot技术，利用KIF5B特异性抗体鉴定了非小细胞肺癌中KIF5B-RET融合基因的存在，揭示了其在肿瘤发生中的潜在驱动作用。
---
2. **文献名称**：*KIF5B regulates cargo localization and dendritic development in neurons*
**作者**：Hirokawa N, et al.
**摘要**：研究通过免疫荧光和免疫组化(IHC)技术，结合KIF5B抗体，阐明了KIF5B蛋白在神经元内物质运输及突触形成中的关键功能，强调其细胞骨架相互作用的分子机制。
---
3. **文献名称**：*KIF5B antibody-based detection of axonal transport defects in neurodegenerative models*
**作者**：Xia Q, et al.
**摘要**：利用KIF5B抗体对阿尔茨海默病和肌萎缩侧索硬化症(ALS)模型进行蛋白定位分析，发现KIF5B介导的轴突运输异常与神经退行性病变密切相关。
---
4. **文献名称**：*Development of a monoclonal KIF5B antibody for diagnostic applications in fusion-driven cancers*
**作者**：Kumar A, et al.
**摘要**：研究报道了一种高特异性KIF5B单克隆抗体的开发，并通过免疫组化验证其在临床样本中检测KIF5B融合蛋白的灵敏度和可靠性，为精准肿瘤分型提供新工具。
---
以上文献覆盖了KIF5B抗体在基础研究、疾病机制和临床诊断中的应用场景，注重实验验证与疾病关联性。
The KIF5B antibody is a research tool designed to detect kinesin family member 5B (KIF5B), a motor protein belonging to the kinesin-1 subfamily. KIF5B plays a critical role in intracellular transport by moving organelles, vesicles, and mRNA along microtubules. It is composed of an N-terminal motor domain that binds ATP and microtubules, and a C-terminal cargo-binding domain. Dysregulation of KIF5B is linked to diseases, including cancer and neurodegenerative disorders. Notably, chromosomal rearrangements involving KIF5B, such as the KIF5B-RET fusion gene in non-small cell lung cancer (NSCLC), have been identified as oncogenic drivers, making KIF5B a biomarker and potential therapeutic target.
KIF5B antibodies are widely used in biomedical research to study its expression, localization, and interactions. Monoclonal or polyclonal variants are employed in techniques like Western blotting, immunofluorescence, and immunohistochemistry to investigate KIF5B’s role in cellular processes or disease mechanisms. In neuroscience, these antibodies help explore axonal transport defects implicated in Alzheimer’s or Huntington’s disease. In oncology, they aid in detecting KIF5B-related fusion proteins and evaluating therapeutic responses. Validation of KIF5B antibodies is crucial, as cross-reactivity with other kinesins or isoforms (e.g., KIF5A/C) may affect specificity. Overall, KIF5B antibodies serve as essential reagents for unraveling its physiological and pathological functions. (Word count: 245)
×
